US Markets: Stocks rise with Nasdaq at record on vaccine hope

Marco Green
July 3, 2020

The companies announced these preliminary findings on Wednesday in a pre-print paper that shows participants in a Phase 1/2 study of the vaccine, called BNT162b1, responded to the immunization and it was found to be well tolerated.

However, gains have been limited given worries the jump in new Covid-19 cases, resulting in California becoming the latest USA state to re-impose lockdown measures, will have on future demand.

How the study was conducted: For the initial study, 45 participants ages 18 to 55 were randomly assigned to either receive a certain dose of the vaccine or placebo.

The preliminary clinical data evaluated 24 subjects who received two injections of 10 µg and 30 µg, and nine subjects who received two doses of placebo control, 21 days apart.

The preliminary data comes from the partners' BNT162 mRNA-based vaccine programme, dubbed Project Lightspeed, which is evaluating four investigational vaccine candidates against SARS-CoV-2, the virus which causes COVID-19.

Those who received the 10 and 30 microgram doses were given two injections, while those who got the larger dose only got one.

According to the World Health Organization, there are 17 coronavirus candidate vaccines in clinical evaluation globally. As a result of this, the participants only received a single dose of this strength of vaccine.

Participants in the 100 µg group were not given a second dose since higher numbers of subjects experienced local reactions and systemic events after the single 100 µg dose, with no significant increases in immunogenicity compared to the 30 µg dose level, BioNTech and Pfizer said.

In short, a sentinel cohort design was utilized for this trial, with progression and dose escalation taking place after reviewing the data from the sentinel cohort at each dose level. Although the researchers utilized convalescent sera as a comparator, the type of immunity (T cells versus B cells) and the level required for protection against COVID-19 are unknown.

Appetite for global equities heightened after data showed record employment growth in the United States at 4.8 million job additions, even as layoffs remained elevated and COVID-19 cases across the country spiked.

"We look forward to providing further data updates on BNT162b1", Sahin said.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER